Methotrexate pen approved to treat Crohn's disease

Metoject (methotrexate) auto-injector can now be used to treat mild to moderate Crohn's disease in adults who are refractory or intolerant to thiopurines (azathioprine or mercaptopurine).

Patients with Crohn's disease can use Metoject as monotherapy or alongside corticosteroid treatment. The pen is used once weekly; initial dosing is 25mg weekly, followed by maintenance dosing of 15mg weekly.

The discontinued syringe presentation of Metoject, which was superseded by the auto-injector in 2014, was previously licensed to treat Crohn's disease.


Want news like this straight to your inbox?
Sign up for our bulletins


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases